Article

Alimera dry eye emollient drop hits market

Alimera Sciences Inc. introduces its lubricant eye drops, Soothe Emollient, the first multi-dose, emollient-based artificial tear product for dry-eye sufferers.

Alimera Sciences Inc. introduces its lubricant eye drops, Soothe Emollient, the first multi-dose, emollient-based artificial tear product for dry-eye sufferers. The product is slated to reach U.S. retail stores by Sept. 15.

Using Restoryl, an advanced lipid restorative, Soothe re-establishes the eye's protective lipid layer to reduce tear evaporation and seal essential moisture, giving patients up to 8 hours of comfort.

Alimera Sciences licensed the artificial tear product in November 2003 from Ocular Research of Boston (ORB), a group of eye-care specialists who focus on dry eye research. The agreement combined the medical expertise of ORB with the ophthalmic commercial experience of Alimera Sciences.

"This product was inspired by and developed for dry eye patients," said Donald Korb, MD, ORB president, in a company statement. "Because Soothe restores the compromised lipid layer of patients' tears, regardless of the particular dry eye state, harmful evaporation is minimized and the ocular surface is protected.

"Thus, doctors can be confident that they are giving their patients long-lasting relief," Dr. Korb said. "After years of perfecting the formula and finding the right partner, I am excited that Soothe will be accessible to patients in such a short time."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.